Get a glimpse into our company and investor data—powered by the PitchBook Platform
Portfolio of Ebola vaccine. The vaccine candidate, called rVSV-EBOV, was originally developed by the Public Health Agency of Canada. It is currently being evaluated in phase-I clinical trials.
This information is reserved for PitchBook Platform users. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.
© 2019 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.